The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 05, 2024

Filed:

Oct. 27, 2021
Applicant:

Hangzhou Calibra Diagnostics Co., Ltd., Zhejiang, CN;

Inventors:

Shanshan Zeng, Hangzhou, CN;

Qi Zhang, Hangzhou, CN;

Baoyu Han, Hangzhou, CN;

Huafen Liu, Hangzhou, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/96 (2006.01); G01N 1/28 (2006.01); G01N 1/38 (2006.01); G01N 30/02 (2006.01); G01N 30/04 (2006.01); G01N 30/06 (2006.01); G01N 30/34 (2006.01); G01N 30/72 (2006.01); G01N 30/88 (2006.01); G01N 33/68 (2006.01); G01N 33/94 (2006.01);
U.S. Cl.
CPC ...
G01N 33/96 (2013.01); G01N 1/286 (2013.01); G01N 1/38 (2013.01); G01N 30/06 (2013.01); G01N 30/34 (2013.01); G01N 30/7233 (2013.01); G01N 33/9493 (2013.01); G01N 2030/027 (2013.01); G01N 2030/045 (2013.01); G01N 2030/8822 (2013.01); G01N 2030/8831 (2013.01); G01N 33/6848 (2013.01);
Abstract

A detection kit for detecting an immunosuppressor in whole blood by high performance liquid chromatography-tandem mass spectrometry and a detection method thereof is provided. An internal standard solution is added with an antioxidant, vitamin E, and mixed with an internal standard diluent containing zinc sulfate heptahydrate, purified water and methanol for sample pretreatment, which not only exerts the function of the internal standard, but also synchronously achieves erythrocyte treatment, protein precipitation and target substance extraction. Various embodiments enable the immunosuppressor to be more stable in a solution matrix, thus promoting the detection accuracy and sensitivity. Various embodiments adopt isotopically-labeled sirolimus as an internal standard of everolimus to substitute isotopically-labeled everolimus, thus overcoming the interference of everolimus on isotopically-labeled everolimus and satisfying the detection requirements. Various embodiments detect four immunosuppressors simultaneously to reduce the cost of the internal standard, and has a lower detection cost, more accurate and stable detection results.


Find Patent Forward Citations

Loading…